



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/656,668	09/07/2000	Jiangchun Xu	210121.484C3	2196

7590 12/04/2001
Jane E R Potter
Seed Intellectual Property Law Group
701 Fifth Avenue
Suite 6300
Seattle, WA 98104-7092

EXAMINER

SHEINBERG, MONIKA B

ART UNIT	PAPER NUMBER
----------	--------------

1631

DATE MAILED: 12/04/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/656,668

Applicant(s)

XU ET AL.

Examiner

Monika B Sheinberg

Art Unit

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 September 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 3,4,6-8,13,22 and 65 is/are pending in the application.
- 4a) Of the above claim(s) 1, 2, 9, 17-21, 23, 24, and 27-64 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 3,4,6-8,13,22 and 65 is/are rejected.
- 7) ☒ Claim(s) 7 is/are objected to.
- 8) ☒ Claim(s) 3,4,6-8,13,22 and 65 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>1 sheet</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION***Election/Restrictions***

Applicants' election of Group II (claims 3-8, 13-16, 22, 25, 26, and 65) and nucleic acid SEQ ID NO: 198 in Paper No. 10, filed 19 September 2001, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (M.P.E.P. § 818.03(a)). The cancellation of claims 5, 14-16, and 26 are acknowledged. The claims under examination are 3, 4, 6-8, 13, 22, and 65. The amended claims 3, 13, 22, and 65 are acknowledged.

Claims 1, 2, 9, 17-21, 23, 24, and 27-64 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected groups, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 7, filed 13 June 2001, and also in Paper No. 10, filed 19 September 2001.

Priority

Applicant's claims for priority to US Patent applications 09/561,778 (05/01/2000) and 09/394,374 (09/10/1999) are acknowledged. However, these applications upon which priority is claimed fails to provide adequate support under 35 U.S.C. 112 for claims 3, 4, 6-8, 13, 22, and 65 of this application. The elected nucleic acid sequence, SEQ ID NO: 198 is not disclosed in either of these applications. Thus priority to these US Patent applications is not considered.

Claim Rejections - 35 USC § 112/101

Art Unit: 1631

The pending claims have been reviewed in light of the Utility Examination Guidelines and Guidelines for Examination of Patent Applications under 35 U.S.C. 112, first paragraph, "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1092-1111, Friday, January 5, 2001.

The examiner is using the following definitions in evaluating the claims for utility.

"Specific" - A utility that is *specific* to the subject matter claimed. This contrasts with a *general* utility that would be applicable to the broad class of the invention.

"Substantial" - A utility that defines a "real world" use. Utilities that require or constitute carrying out further research to identify or reasonably confirm a "real world" context of use are not substantial utilities.

"Credible" - Credibility is assessed from the perspective of one of ordinary skill in the art in view of the disclosure and any other evidence of record that is probative of the applicant's assertions. That is, the assertion is an inherently unbelievable undertaking or involves implausible scientific principles.

"Well-established" - a specific, substantial, and credible utility which is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material, alone or taken with the knowledge of one skilled in the art.

35 U.S.C. § 101 reads as follows:

"Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title".

Claims 3, 4, 6-8, 13, 22, and 65 are rejected under 35 U.S.C. § 101 because the claimed invention lacks patentable utility due to its not being supported by either specific and/or substantial utility or a well established utility.

The claimed nucleic acid, SEQ ID NO: 198, is not supported by a specific asserted utility because the disclosed use of this composition is not specific and is generally applicable to any nucleic acid. The specification states that the nucleic acid compound may be useful as a hybridization probe, primer, peptide encoding. In fact, the specification summarized modern biotechnology generally but never connects any of the specifically elected sequences to any

Art Unit: 1631

particular or specific utility. This wishlist desire for a utility for the claimed sequences falls short of a readily available utility. Similarly, protein may be used for antibody production, pharmaceutical compositions and vaccines. These are non-specific uses that are applicable to nucleic acid(s) and/or proteins in general and not particular or specific to the nucleic acid being claimed.

Further, the claimed nucleic acids are not supported by a substantial utility because no substantial utility has been established for the claimed subject matter. For example, a nucleic acid may be utilized to obtain "the ovarian carcinoma protein" (specification, p. 2, lines 15-16). Besides there not being just one ovarian carcinoma protein, 210 contiguous nucleic acids of the SEQ ID NO: 198 are of 100% identity to GenBank accession number AI023799 (entered 28-AUG-1998), which is derived from a male liver and spleen organ. Table VII of the specification only discloses SEQ ID NO: 198 from chromosome 22 from the library POTS2. The selection of a sequence from a library and asserting an association to an ovarian carcinoma protein is not evidence of utility. The specification thus lacks a disclosure of any intrinsic utility or bioactivity of the elected sequence alone; such as if the sequence encodes a functional or useful domain of the peptide it encodes. The need for such research clearly indicates that the protein and/or its function is not disclosed as to a currently available or substantial utility. Identifying and studying the properties of a protein itself or the mechanisms in which the protein is involved does not define a "real world" context or use. Similarly, the other listed and asserted utilities as summarized above or in the instant specification are neither substantial nor specific due to being generic in nature and applicable to a myriad of such compounds. Note, because the claimed invention is not supported by a specific and substantial asserted utility for the reasons set forth

Art Unit: 1631

above, credibility has not been assessed. Neither the specification as filed nor any art of record discloses or suggests any property or activity for the nucleic acid and/or protein compound(s) such that another non-asserted utility would be well established for the compounds.

Claims 3, 4, 6-8, 13, 22, and 65 are also rejected under 35 U.S.C. § 112, first paragraph. Specifically, since the claimed invention is not supported by a specific, substantial, and credible utility, or, alternatively, a well established utility for the reasons set forth above, one skilled in the art would not know how to use the claimed invention.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 3, 4, 6-8, 13, 22, and 65 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specification discloses SEQ ID NO: 198, asserted to encode an ovarian carcinoma protein. The full length exact sequence of SEQ ID NO: 198 per se meet the written description and enablement provisions of 35 USC 112, first paragraph. However, Claims 3, 6-8, 13, 22, and 65 are directed to encompass gene sequences, and fragments of sequences of SEQ ID NO: 198, corresponding sequences from other species, mutated fragment sequences, allelic variants, splice variants, and so forth. None of these additional sequences meet the written description provision of 35 USC 112, first paragraph. The specification provides insufficient written description to

Art Unit: 1631

support the genus encompassed by the claim. This is a rejection based on a lack of WRITTEN DESCRIPTION.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

With the exception of SEQ ID NO: 198; the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. The nucleic acid itself is required. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. In Fiddes v. Baird, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

Finally, University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that:

...To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." Lockwood v. American Airlines, Inc. , 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In re Gosteli , 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." Lockwood , 107 F.3d at 1572, 41 USPQ2d at 1966.

Art Unit: 1631

An adequate written description of a DNA, such as the cDNA of the recombinant plasmids and microorganisms of the '525 patent, "requires a precise definition, such as by structure, formula, chemical name, or physical properties," not a mere wish or plan for obtaining the claimed chemical invention. *Fiers v. Revel*, 984 F.2d 1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). Accordingly, "an adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself." *Id.* at 1170, 25 USPQ2d at 1606.

The name cDNA is not itself a written description of that DNA; it conveys no distinguishing information concerning its identity. While the example provides a process for obtaining human insulin-encoding cDNA, there is no further information in the patent pertaining to that cDNA's relevant structural or physical characteristics; in other words, it thus does not describe human insulin cDNA. Describing a method of preparing a cDNA or even describing the protein that the cDNA encodes, as the example does, does not necessarily describe the cDNA itself. No sequence information indicating which nucleotides constitute human cDNA appears in the patent, as appears for rat cDNA in Example 5 of the patent. Accordingly, the specification does not provide a written description of the invention of claim 5.

Therefore, only SEQ ID NO: 198, but not the full breadth of the claims meet the written description provision of 35 USC 112, first paragraph. The species specifically disclosed is not representative of the genus because the genus is highly variant. Applicant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 3, 4, 6-8, 13, 22, and 65 are rejected, as discussed below, under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1631

Claims 3, 4, 6, 13, 22, and 65 are vague and indefinite as to what is meant therein by the limitation "the complement". A possible interpretation is that the complement must be of the same length and be the full and exact complement of the recited SEQ ID NO: sequence. Another interpretation is that any complement is meant including those with less than 100% complementarity, such as 90%, 50%, or even 10%. Clarification of the metes and bounds of the claim is requested via clearer claim wording. Claims 7 and 8 are rendered vague and indefinite due to dependency from the indefinite claim 6.

Claim 65 is vague and indefinite as to what is meant therein by the limitation of "a diagnostic reagent for use in a polymerase chain reaction or hybridization assay" (step b). The two assay are different and require different diagnostic agents. Thus the claim lacks clarity as to which diagnostic agent it is claiming that is used for both assays.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claims 3, 4, 6-8, and 22 are rejected under 35 U.S.C. 102(b) as being anticipated by the nucleic acid sequences of GenBank, accession numbers AI023799 and AI307373.

Art Unit: 1631

The two GenBank accession numbers AI023799 and AI307373 are nucleic acid sequences that anticipate the limitations set forth in claims 3, 6, and 22. Each sequence has various lengths of contiguous stretches that are identical to or complementary to the SEQ ID NO: 198. These stretches have greater than 90% identity to the elected sequence as well. The sequences are described as clones thus anticipate claims 4, 7, and 8.

Claim 65 is rejected under 35 U.S.C. 102(e) as being anticipated by the following two US Patents 5,585,232 (Far; 17-Dec-1996) and 5,589,337 (Far, 31-Dec-1996).

Far teaches diagnostic kits in both US Patents using sequences (both SEQ ID NO: 2) that meet the limitations set in claim 65. US Patent 5,585,23 teaches in column 21, last paragraph the construction of the their primer sequence, SEQ ID NO: 2 through PCR techniques. The sequence is greater than 10 nucleotides in length, and with 100% identity, would hybridize under stringent conditions. US Patent 5,589,337 teaches the same in column 23, 3rd paragraph. Thus claim 65 is anticipated by Far's two US Patents.

No claim is allowed.

Information Disclosure Statement

The information disclosure statement filed 25 January 2001 fails to comply with 37 CFR 1.98(a)(2), each publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered. Only the foreign patent WO 98/37418 was provided.

Art Unit: 1631

Inquiries

— Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703) 308-4242, or (703) 308-4028.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Monika B. Sheinberg, whose telephone number is (703) 306-0511. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael P. Woodward, can be reached on (703) 308-4028.


Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Patent Analyst, Tina Plunkett, whose telephone number is (703) 305-3524, or to the Technical Center receptionist whose telephone number is (703) 308-0196.

December 3, 2001

Monika B. Sheinberg

Art Unit 1631

MBS


MICHAEL P. WOODWARD
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600